Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

222 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Progress in understanding the molecular pathogenesis of human lung cancer.
Sekido Y, Fong KM, Minna JD. Sekido Y, et al. Biochim Biophys Acta. 1998 Aug 19;1378(1):F21-59. doi: 10.1016/s0304-419x(98)00010-9. Biochim Biophys Acta. 1998. PMID: 9739759 Review.
TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
Oh Y, Proctor ML, Fan YH, Su LK, Hong WK, Fong KM, Sekido YS, Gazdar AF, Minna JD, Mao L. Oh Y, et al. Among authors: sekido ys. Oncogene. 1998 Sep 3;17(9):1141-8. doi: 10.1038/sj.onc.1202029. Oncogene. 1998. PMID: 9764824
Molecular pathogenesis of malignant mesothelioma.
Sekido Y. Sekido Y. Carcinogenesis. 2013 Jul;34(7):1413-9. doi: 10.1093/carcin/bgt166. Epub 2013 May 14. Carcinogenesis. 2013. PMID: 23677068 Review.
EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, Yokoi K, Osada H, Imaizumi K, Hasegawa Y, Shimokata K, Sekido Y. Yokoyama T, et al. Among authors: sekido y. Cancer Sci. 2006 Aug;97(8):753-9. doi: 10.1111/j.1349-7006.2006.00233.x. Cancer Sci. 2006. PMID: 16863509
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation.
Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. Hayashita Y, et al. Among authors: sekido y. Cancer Res. 2005 Nov 1;65(21):9628-32. doi: 10.1158/0008-5472.CAN-05-2352. Cancer Res. 2005. PMID: 16266980
The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, Hasegawa Y. Sato M, et al. Among authors: sekido y. Oncogene. 2002 Jul 18;21(31):4822-9. doi: 10.1038/sj.onc.1205581. Oncogene. 2002. PMID: 12101420
RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.
Sato N, Fukui T, Taniguchi T, Yokoyama T, Kondo M, Nagasaka T, Goto Y, Gao W, Ueda Y, Yokoi K, Minna JD, Osada H, Kondo Y, Sekido Y. Sato N, et al. Among authors: sekido y. Int J Cancer. 2007 Feb 1;120(3):543-51. doi: 10.1002/ijc.22328. Int J Cancer. 2007. PMID: 17096327
Molecular genetics of lung cancer.
Sekido Y, Fong KM, Minna JD. Sekido Y, et al. Annu Rev Med. 2003;54:73-87. doi: 10.1146/annurev.med.54.101601.152202. Epub 2001 Dec 3. Annu Rev Med. 2003. PMID: 12471176 Review.
eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.
Tanaka I, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. Tanaka I, et al. Among authors: sekido y. Cancer Sci. 2018 Jun;109(6):1843-1852. doi: 10.1111/cas.13602. Epub 2018 May 25. Cancer Sci. 2018. PMID: 29624814 Free PMC article.
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.
Kakumu T, Sato M, Goto D, Kato T, Yogo N, Hase T, Morise M, Fukui T, Yokoi K, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. Kakumu T, et al. Among authors: sekido y. Cancer Sci. 2017 Apr;108(4):732-743. doi: 10.1111/cas.13185. Epub 2017 Apr 25. Cancer Sci. 2017. PMID: 28165654 Free PMC article.
222 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback